Cardio-oncology

Forming the foundations of your cardio-oncology care pathway


Supporting cardiovascular prevention workflows in line with the 2022 ESC Guidelines on cardio-oncology

    Managing cardiotoxicity risks at every step

    Cancer treatment is a challenging and highly stressful time for patients – but it also brings dangers for their cardiovascular health. Since cancer patients have on average a 2-6 times higher cardiovascular disease mortality risk than the general population1, prompt, reliable identification of at-risk patients is crucial. And once treatment is underway, close monitoring could help cardiologists detect potential biomarkers that may indicate the early stages of cardiac toxicity.

    The recently published European Society of Cardiology (ESC) Guidelines for Cardio-oncology (available here2) reflect these priorities for the prevention and monitoring of cardiotoxicity risks. And with our comprehensive workflow solutions and advanced cardiovascular ultrasound systems, we’re ready to support you and your patients every step of the way along their cancer treatment journey.

    Worldwide, an estimated
    28.4 million new cancer cases are projected to occur in 2040,
    a
    47% rise from 2020 – making cardiology care for cancer survivors increasingly important3

    Supporting your cardiotoxicity monitoring and prevention strategies

    Cardiotoxicity monitoring and prevention strategies infographic

    Supporting your cardiotoxicity monitoring and prevention strategies

    How Philips solutions and capabilities can help

    Solutions

    Photo of Dr Lopez
    Dynamic HeartModelA.I. and AutoStrain provide valuable insights to support cardiovascular monitoring and cardiotoxicity prevention, in close collaboration with oncologists and hematologists.”Dynamic HeartModelA.I. and AutoStrain provide valuable insights to support cardiovascular monitoring and cardiotoxicity prevention, in close collaboration with oncologists and hematologists.”

    Dr Teresa López Fernández

    Cardiac Imaging and Cardio-Oncology Unit Leader, La Paz University Hospital, Madrid, Spain

    We are always interested in engaging with you.

    Let us know how we can help.

    1
    Select your area of interest
    2
    Contact details

    References

    1 www.escardio.org/The-ESC/Press-Office/Press-releases/Cancer-patients-are-at-higher-risk-of-dying-from-heart-disease-and-stroke
    2 Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., Cutter, D. J., De Azambuja, E., De Boer, R. A., Dent, S. F., Farmakis, D., Gevaert, S. A., Gorog, D. A., Herrmann, J., Lenihan, D. (2022). 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal, 43(41), 4229–4361. https://doi.org/10.1093/eurheartj/ehac244.
    3 Sung, H., Ferlay, J., Siegel, RL., Laversanne, M., Soerjomataram, I., Jemal, A., Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021: 71: 209- 249. https://doi.org/10.3322/caac.21660.
    4 Philips Cardiovascular Workspace is the commercial name of the medical device Philips IntelliSpace Cardiovascular.
    5 Advanced Visualization Workspace is the commercial name for IntelliSpace Portal.

    You are about to visit a Philips global content page

    Continue

    You are about to visit a Philips global content page

    Continue

    Our site can best be viewed with the latest version of Microsoft Edge, Google Chrome or Firefox.